Spruce Net Debt vs Cash Analysis
| SPRB Stock | USD 0.48 0.01 2.04% |
Spruce Biosciences financial indicator trend analysis is much more than just breaking down Spruce Biosciences prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Spruce Biosciences is a good investment. Please check the relationship between Spruce Biosciences Net Debt and its Cash accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.
Net Debt vs Cash
Net Debt vs Cash Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Spruce Biosciences Net Debt account and Cash. At this time, the significance of the direction appears to have pay attention.
The correlation between Spruce Biosciences' Net Debt and Cash is -0.98. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Cash in the same time period over historical financial statements of Spruce Biosciences, assuming nothing else is changed. The correlation between historical values of Spruce Biosciences' Net Debt and Cash is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Spruce Biosciences are associated (or correlated) with its Cash. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash has no effect on the direction of Net Debt i.e., Spruce Biosciences' Net Debt and Cash go up and down completely randomly.
Correlation Coefficient | -0.98 |
| Relationship Direction | Negative |
| Relationship Strength | Significant |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Cash
Cash refers to the most liquid asset of Spruce Biosciences, which is listed under current asset account on Spruce Biosciences balance sheet and usually includes currency, coins, checking accounts, and not deposited checks received from Spruce Biosciences customers. The amounts must be unrestricted with restricted cash listed in a different Spruce Biosciences account. The total amount of money in the form of currency that a company has in its possession. This includes all bills, coins, and funds in bank accounts.Most indicators from Spruce Biosciences' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Spruce Biosciences current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 62.6 M, whereas Selling General Administrative is forecasted to decline to about 8.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Reconciled Depreciation | 68K | 74K | 78K | 49.3K | Total Operating Expenses | 42.1M | 47.3M | 62.1M | 37.4M |
Spruce Biosciences fundamental ratios Correlations
Click cells to compare fundamentals
Spruce Biosciences Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Spruce Biosciences fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 4.7M | 162.9M | 126.5M | 85.6M | 103.9M | 89.5M | |
| Other Current Liab | 1.2M | 3.3M | 5.7M | 9.3M | 14.3M | 15.1M | |
| Total Current Liabilities | 4.3M | 9.8M | 8.9M | 12.4M | 24.5M | 25.7M | |
| Total Stockholder Equity | (30.6M) | 149.4M | 111.4M | 68.5M | 76.5M | 65.5M | |
| Net Tangible Assets | (30.6M) | 149.4M | 111.4M | 68.5M | 78.8M | 61.8M | |
| Net Debt | 521K | (151.0M) | (36.6M) | (18.3M) | (91.7M) | (87.1M) | |
| Retained Earnings | (31.3M) | (60.8M) | (103.1M) | (149.3M) | (197.2M) | (187.4M) | |
| Accounts Payable | 1.9M | 3.6M | 2.8M | 1.4M | 3.3M | 2.8M | |
| Cash | 3.9M | 157.2M | 42.7M | 24.5M | 96.3M | 60.3M | |
| Non Current Assets Total | 40K | 2.5M | 34.6M | 2.0M | 1.8M | 1.7M | |
| Non Currrent Assets Other | 40K | 477K | 653K | 55.2M | 582K | 552.9K | |
| Other Assets | 40K | 2.5K | 513K | 640K | 1.0 | 0.95 | |
| Cash And Short Term Investments | 3.9M | 157.2M | 89.0M | 79.1M | 96.3M | 78.8M | |
| Common Stock Shares Outstanding | 22.3M | 23.3M | 23.4M | 23.5M | 38.5M | 24.9M | |
| Liabilities And Stockholders Equity | 4.7M | 162.9M | 126.5M | 85.6M | 103.9M | 89.5M | |
| Non Current Liabilities Total | 31.0M | 3.7M | 6.2M | 4.7M | 3.0M | 2.8M | |
| Other Current Assets | 513K | 3.2M | 2.9M | 4.5M | 5.8M | 3.2M | |
| Other Stockholder Equity | 664K | 373.1M | 214.7M | 218.4M | 273.7M | 198.2M | |
| Total Liab | 35.3M | 13.5M | 15.1M | 17.2M | 27.4M | 17.5M | |
| Net Invested Capital | (26.2M) | 153.9M | 116.2M | 73.4M | 79.8M | 69.6M | |
| Total Current Assets | 4.7M | 160.4M | 91.9M | 83.6M | 102.2M | 82.0M | |
| Net Working Capital | 349K | 150.6M | 83.0M | 71.2M | 77.7M | 70.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Spruce Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Spruce Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Spruce Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Spruce Biosciences Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spruce Biosciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spruce Stock refer to our How to Trade Spruce Stock guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spruce Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.95) | Revenue Per Share 0.173 | Quarterly Revenue Growth (0.80) | Return On Assets (0.30) | Return On Equity (0.58) |
The market value of Spruce Biosciences is measured differently than its book value, which is the value of Spruce that is recorded on the company's balance sheet. Investors also form their own opinion of Spruce Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Spruce Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spruce Biosciences' market value can be influenced by many factors that don't directly affect Spruce Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spruce Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.